Homepage > Company > Media > Pharma News > 2024 > MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing

MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing

MIRA Pharmaceuticals has announced promising preclinical results for its oral ketamine analog, Ketamir-2, showing it does not induce hyper-locomotor activity, a psychotic symptom common with traditional ketamine use.

This indicates Ketamir-2 could offer safer mental health treatments. Conducted with Biotrial, the study evaluated Ketamir-2's effects on spontaneous locomotor activity in mice. Unlike traditional ketamine, Ketamir-2 did not trigger hyperlocomotion, suggesting reduced risks of psychotic behaviors and misuse.

MIRA plans to submit an IND application to the FDA by year-end. This development positions Ketamir-2 for broader psychiatric and neurologic applications, potentially reducing healthcare costs for conditions like treatment-resistant depression, which currently costs the U.S. $43.8 billion annually.

Further studies on Ketamir-2's safety and efficacy are ongoing, with potential applications for cancer pain and PTSD.

June 28, 2024

Read also

Phase 3 trials of treatment combo for hepatitis D expected in 2025

On the heels of positive Phase 2 clinical trial data, Vir Biotechnology is planning for the 2025 launch of a Phase 3 program, dubbed ECLIPSE, to test its treatment combination of tobevibart and elebsi...

Breakthrough Therapy Designation Market Is Booming Worldwide 2024-2032

The Breakthrough Therapy Designation market has witnessed significant growth over the past decade, driven by advancements in technology, shifting consumer preferences, and increasing investments from ...

Veeva Commercial Summit: Increased investment in medical affairs by pharma companies

Veeva’s VP of global medical, Christoph Bug, emphasises the importance of scientific exchange between clinical experts and pharmaceutical companies.

Remix

Remix Therapeutics to Present Preclinical Data Demonstrating Anti-Leukemic Activity of REM-422 in AML at the 66th American Society of Hematology Annual Meeting and Exposition (ASH)